The FDAs Race and Ethnic Diversity Plan Guidance: How prepared is your organization?

To align diversity plans to FDA's draft diversity guidance will require sponsors to shift from trial-level considerations to disease-level planning and partnership strategies. In this virtual roundtable Xoli Belgrave, Senior Director, Patient Innovation Center, is joined by other CRO, site and pharma SMEs to discuss the need for early engagement with sponsors and research partners as well as site-level strategies to reach underrepresented patient populations.

Return to Insights Center